Privacy Policy

Machaon Diagnostics is committed to protecting the privacy of every person who visits our website so that each person will feel free to gather information, make inquiries/comments, and explore our service offerings. Should you have any questions about this policy or our practices, please send an email to info@MachaonDiagnostics.com or write to us at:

Machaon Diagnostics
Attention: Privacy Officer
3023 Summit Street
Oakland, CA 94609

You can also call us at 800-566-3462.

As part of Machaon’s effort to protect the privacy of your personal information while visiting our website, this web privacy statement serves to inform you of the privacy standards used to ensure the security and confidentiality of your information. The following information details how Machaon uses information that you provide to us via the website and answers commonly asked questions regarding the privacy of your individual information.

What Personal Information We Collect

Machaon Diagnostics does not ask you to provide personal health care information to us through our general website. We obtain personally identifying information about you only if you voluntarily choose to provide such information via correspondence with Machaon. Correspondence conducted via the Machaon website is stored on a third-party server and then downloaded by Machaon personnel.

How We Use Personal Information That We Collect Online

Internal Uses

We may use your personal information within Machaon Diagnostics: (1) to provide you with the services you request or by your healthcare provider acting on your behalf; (2) to answer questions about our services or use of our website; (3) to conduct customer surveys; and (4) to contact you about the products and services that we offer.

Disclosure of Personal Information to Third Parties

We will not disclose any personal information to any third party (excluding our contractors to whom we may provide such information for the limited purpose of providing services to us and who are obligated to keep the information confidential), unless (1) you have authorized us to do so; (2) we are legally required to do so, for example, in response to a subpoena, court order or other legal process and/or, (3) it is necessary to protect our property rights related to this website. We also may share aggregate, non-personal information about website usage with unaffiliated third parties. This aggregate information does not contain any personal information about our users.

Cookie Placement

The Machaon Diagnostics website, like many other commercial sites, may use a standard technology called “cookies” to collect information about how our site is used. Cookies were designed to help a website operator determine that a particular user had visited the site previously and thus save and remember any preferences that may have been set. We may use cookies to keep track of information about your current web browsing session which will be discarded as soon as you log out or close your web browser. This information also allows us to statistically monitor how many people are using our site and for what purpose. We may also make use of “persistent or memory based” cookies, which remain on your computer’s hard drive until you delete them. An example of our use of these cookies is to pre-populate forms you complete on our website based on information you have previously provided to us. Although you have the ability to modify your browser to either accept all cookies, notify you when a cookie is sent, or reject all cookies, it may not be possible to utilize our services if you reject cookies.

Machaon Diagnostics uses the services of Google Analytics, and may use other similar services, to collect and analyze statistical data about visitors to our website. We also use Google advertising services, and may use other similar services, to arrange for you to see Machaon Diagnostics advertisements when you visit certain third party websites. These analytic and advertising services do not collect personally identifiable information. You may elect to opt out of the use of non-personally identifiable data by Google Analytics by downloading and installing an add-on to your web browser found here. You may find out more about how Google Analytics collects and processes data by visiting “How Google uses data when you use our partners’ sites or apps,” found here. You may also opt out of the Google AdWords service we use to serve ads, and which service also collects non-personally identifiable information, by visiting the Google Ad Settings page here. For additional information about opting out of interest-based advertising, please visit this page.

How We Protect Information Online

We exercise great care to protect your personal information. This includes, among other things, using industry standard techniques such as firewalls, encryption, and intrusion detection. As a result, while we strive to protect your personal information, we cannot ensure or warrant the security of any information you transmit to us or receive from us. This is especially true for information you transmit to us via email since we have no way of protecting that information until it reaches us since email does not have the security features that are built into our websites.

In addition, we limit Machaon Diagnostics’ employees and contractors’ access to personal information. Only those employees and contractors with a business reason to know have access to this information. We educate our employees about the importance of maintaining confidentiality of customer information.

We review our security arrangements from time to time as we deem appropriate.

Links to Other Sites

We want to provide site visitors valuable information, services and products. Featured programs and other site content within the Machaon Diagnostics site may link our users to third party sites. Machaon Diagnostics does not control and is not responsible for practices of any third-party websites.

Note

From time to time, we may change this privacy statement. For example, as we update and improve our services, new features may require modifications to the privacy statement. Accordingly, please check back periodically.

Date: May 25, 2018

Panels
Tests
Order Forms
Collection Guide
Education and Publications
Clinical Trial Services
Patients

Panels

Panel Name STAT Turnaround Time Draw Kit Available (Y/N) Sample Requirement
Hypophosphatasia/Osteogenesis Imperfecta Genetic Panel 48 hours (M-F, two consecutive business days required) Yes EDTA whole blood
Polycystic Kidney Disease (PKD) Genetic Panel 48 hours (M-F, two consecutive business days required) Yes EDTA whole blood
PlateletGenex Thrombocytopenia Panel 48 hours (M-F, two consecutive business days required) Yes EDTA Whole Blood
C3 Glomerulopathy Genetic Panel 48 hours (M-F, two consecutive business days required) Yes EDTA whole blood
Thrombophilia Genetic Panel 48 hours (M-F, two consecutive business days required) Yes EDTA whole blood
Factor XIII Genetic Panel 48 hours (M-F, two consecutive business days required) Yes EDTA whole blood
Dysfibrinogenemia Genetic Panel 48 hours (M-F, two consecutive business days required) Yes EDTA whole blood
Hemophilia-Complete Severe Bleeding Genetic Panel 48 hours (M-F, two consecutive business days required) Yes EDTA whole blood
vWD-Complete Genetic Panel 48 hours (M-F, two consecutive business days required) Yes EDTA whole blood
PlateletGenex Functional Defect Panel 48 hours (M-F, two consecutive business days required) Yes EDTA whole blood
Alport Syndrome Genetic Panel 48 hours (M-F, two consecutive business days required) Yes EDTA whole blood
aHUS Genetic Panel 48 hours (M-F, two consecutive business days required) Yes EDTA whole blood
Prolonged aPTT / PT Evaluation Panel < 24 hours No citrated plasma
Heparin Antibody Confirmation Panel < 24 hours (M-F) Yes serum
Mild Bleeding Disorder Panel < 24 hours No citrated whole blood
Hypercoagulability Panel < 24 hours No citrated plasma
Lupus Anticoagulant Screen < 24 hours No citrated plasma
Plavix Sensitivity Panel < 24 hours Yes citrated whole blood
von Willebrand Factor Profile with Multimer < 5 days No citrated plasma
Platelet Aggregation Study – Comprehensive < 24 hours No citrated whole blood
Dysfibrinogenemia Panel < 24 hours No citrated plasma
Antiphospholipid Syndrome Criteria Panel < 24 hours Yes serum

Tests

Test Name STAT Turnaround Time Draw Kit Available (Y/N) Sample Requirement
Clinical Comments and Consultation from Medical Director < 24 hours No
Factor VIII (8) Activity – Chromogenic (Bovine reagent) – Coming Soon (Oct. 2018) <24 hours, coming soon No citrated plasma
Antiphosphotidylserine antibody No serum
s-c5B9 Level No EDTA whole blood
Antithrombin III Gene Sequencing 48 hours (M-F, two consecutive business days required) Yes EDTA whole blood
Factor II Gene Sequencing 48 hours (M-F, two consecutive business days required) Yes EDTA Whole Blood
Factor V Gene Sequencing 48 hours (M-F, two consecutive business days required) Yes EDTA whole blood
Factor VIII Gene Sequencing 48 hours (M-F, two consecutive business days required) Yes
PAI-1 Gene Sequencing 48 hours (M-F, two consecutive business days required) Yes EDTA whole blood
MTHFR Gene Sequencing 48 hours (M-F, two consecutive business days required) No EDTA whole blood
ADAMTS-13 Gene Sequencing 48 hours (M-F, two consecutive business days required) Yes EDTA whole blood
Plasminogen Gene Sequencing 48 hours (M-F, two consecutive business days required) Yes EDTA whole blood
Protein C Gene Sequencing 48 hours (M-F, two consecutive business days required) Yes EDTA whole blood
Protein S Gene Sequencing 48 hours (M-F, two consecutive business days required) Yes EDTA Whole Blood
Anti-CFH Antibody 48 hours Yes plasma
PFA – Screen (Platelet Function Assessment) < 24 hours No citrated whole blood
ADAMTS-13 Activity < 24 hours (7 days a week) Yes citrated plasma
Heparin Antibody Confirmation < 24 hours (M-F) Yes serum
Heparin (UFH) Level < 24 hours No citrated plasma
Platelet Aggregation Study – Comprehensive < 24 hours No citrated whole blood
Warfarin Sensitivity Genotype (CYP2C9 and VKORC1) < 1 week No EDTA whole blood
Thrombin Time < 24 hours No citrated plasma
Thrombin/Antithrombin Complex < 1 week No citrated plasma
von Willebrand Factor Antigen < 24 hours No citrated plasma
von Willebrand Factor Multimer < 5 days No citrated plasma
PT Mixing Study < 24 hours No citrated plasma
Reptilase Clotting Time < 1 week No citrated plasma
Ristocetin Cofactor Activity < 24 hours No citrated plasma
Ristocetin-induced Platelet Aggregation < 24 hours No citrated whole blood
Rivaroxaban (Xarelto) Level < 24 hours No citrated plasma
Russell Viper Venom Time (dilute) < 24 hours No citrated plasma
Thrombin Generation (normalized-ETP) < 24 hours No citrated plasma
Protein S Activity < 24 hours No citrated plasma
Protein S Antigen (Free) < 1 week No citrated plasma
Protein S Antigen (Total) < 1 week No citrated plasma
Prothrombin Fragment 1.2 (F1.2) < 1 week No citrated plasma
Prothrombin Gene Mutation < 24 hours No EDTA whole blood
Prothrombin Time < 24 hours No citrated plasma
Plavix Sensitivity – Genotype (CYP2C19 Genotyping) < 24 hours No EDTA whole blood
Aspirin Sensitivity – LTA (AA-induced Platelet Inhibition) < 24 hours No citrated whole blood
Ticagrelor Sensitivity – LTA (ADP-induced Platelet Inhibition) < 24 hours citrated whole blood
Brilinta Sensitivity – LTA (ADP-induced Platelet Inhibition) < 24 hours No citrated whole blood
Plavix Sensitivity – LTA (ADP-induced Platelet Inhibition) < 24 hours No citrated whole blood
Protein C Activity < 24 hours No citrated plasma
Protein C Antigen < 1 week No citrated plasma
Plasminogen Activator Inhibitor Activity < 10 days No citrated plasma
Plasminogen Activity < 5 days No citrated plasma
Plasminogen Antigen < 5 days No citrated plasma
Platelet Electron Microscopy Study No ACD whole blood
Platelet Antibody ID – Direct (GPIIb/IIIa, GP Ib/IX, GPIa/IIa) < 24 hours No EDTA whole blood
Platelet Antibody ID – Indirect (GPIIb/IIIa, GP Ib/IX, GPIa/IIa) < 24 hours No serum
Inhibitor Screen (aPTT Factors) < 24 hours No citrated plasma
Inhibitor Screen (PT Factors) < 24 hours No citrated plasma
Inhibitor Titer (aPTT Factors) < 24 hours No citrated plasma
Inhibitor Titer (PT Factors) < 24 hours No citrated plasma
Lupus Anticoagulant Index < 24 hours No citrated plasma
MTHFR (A1298C) Gene Mutation < 1 week No EDTA whole blood
MTHFR (C677T) Gene Mutation < 24 hours No EDTA whole blood
Heparin Antibody ELISA (reflex) < 24 hours (7 days a week) Yes serum
Heparin (LMWH) Level < 24 hours No citrated plasma
Hexagonal Phospholipid aPTT < 1 week No citrated plasma
Homocysteine < 5 days No serum
Factor X (10) Activity < 24 hours No citrated plasma
Factor X (10) Activity – Chromogenic < 1 week No citrated plasma
Factor X (10) Antigen < 1 week No citrated plasma
Factor XI (11) Activity < 24 hours No citrated plasma
Factor XII (12) Activity < 24 hours No citrated plasma
Factor XIII (13) Activity – Quantitative < 1 week No citrated plasma
Fibrinogen Activity < 24 hours No citrated plasma
Fibrinogen Antigen < 1 week No citrated plasma
Fondaparinux (Arixtra) Level < 24 hours No citrated plasma
Dabigatran (Pradaxa) Level < 24 hours No citrated plasma
Euglobulin Clot Lysis Time < 1 week No citrated plasma
Factor II (2) Activity < 24 hours No citrated plasma
Factor V (5) Activity < 24 hours No citrated plasma
Factor V (5) Leiden Gene Mutation < 24 hours No EDTA whole blood
Factor VII (7) Activity < 24 hours No citrated plasma
Factor VIII (8) Activity < 24 hours No citrated plasma
Factor IX (9) Activity < 24 hours No citrated plasma
Antithrombin III Activity < 24 hours No citrated plasma
Antithrombin III Antigen < 1 week No citrated plasma
aPTT < 24 hours No citrated plasma
aPTT Mixing Study < 24 hours No citrated plasma
aPTT-FS (Factor Sensitive Reagent) < 24 hours No citrated plasma
aPTT-LA (Lupus Sensitive Reagent) < 24 hours No citrated plasma
aPTT-LA Mixing Study < 24 hours No citrated plasma
aPTT-FS Mixing Study < 24 hours No citrated plasma
Beta-2 Glycoprotein I Antibody (IgG, IgM, IgA) < 1 week No serum
ADAMTS-13 Antibody < 3 days Yes citrated plasma
ADAMTS-13 Inhibitor < 24 hours (7 days a week) Yes citrated plasma
Alpha-2 Antiplasmin Activity < 1 week No citrated plasma
Anticardiolipin Antibody (IgG, IgM, IgA) < 24 hours No serum
Activated Protein C – Resistance < 1 week No citrated plasma

Order Forms

Machaon Diagnostics has provided several downloadable documents to assist in ordering, processing and billing. Below please find links to our most frequently requested documents.

Collection Guide

Specimen processing is one of the most important aspects in the generation of accurate and reliable lab results. Many variables, such as, anticoagulant ratio, storage time and temperature, and surface of containers and drawing components can affect test results.

Machaon Diagnostics follows and recommends the use of the third edition of the National Committee for Clinical Laboratory Standards (NCCLS) guideline H21-A3: Collection, Transport, and Processing of Blood Specimens for Coagulation Testing and General Performance of Coagulation Assays.

Please contact the lab with any shipping questions

Specimen Collection

Frozen Citrated Plasma
Frozen citrated plasma is the specimen of choice for clotting assays and some ELISA testing. The anticoagulant used for these assays is 105 – 109 mmol/L, 3.13% – 3.2% of the dihydrate form of trisodium citrate (Na3C6H5O7 2H2O), buffered or nonbuffered.

Patients with hematocrit values above 55% should have their final citrate concentration corrected using the following equation:

X = (100 – PCV) / (595 – PCV) WB Volume

Where X is citrate volume required to prepare a whole blood volume (WB Volume) from a patient with a certain percent packed cell volume (PCV).

Please follow the listed suggestions for collection of citrated plasma samples.

  • A 1:9 ratio of anticoagulant to whole blood is imperative
  • Blood should be drawn directly into anticoagulant if possible
  • Syringe draws should be added to anticoagulant within 1 minute
  • Syringe draws should use no more that a 20mL volume syringe
  • A two-syringe technique is preferred for syringe draws
  • Coagulation draws should be the 2nd or 3rd tube drawn
  • Catheter draws should be avoided or under the advice of the attending physician
  • All tubes should be inverted at least 4 times to ensure adequate mixing
  • Suitable needle gauges range from 19 – 22 for coagulation and platelet testing
  • Cell-free plasma must contain less than 10,000 platelets/µL
  • Centrifugation should be performed at 1,500 × g for 15 or more minutes
  • Aliquots are frozen (<= -20ºC) promptly to minimize factor degradation
  • Specimens are shipped frozen on dry ice (-78.5ºC)

Frozen Serum
Frozen serum is the specimen of choice for most immunoglobulin detecting assays and many ELISA based tests. Whole blood is drawn into a glass or plastic tube possibly containing an activator. Please follow the tube manufacturer’s guidelines for tube handling and processing.

Please follow the listed suggestions for collection of serum samples.

  • Plastic tubes containing an activator should be inverted at least 4 times
  • Glass tubes without activator should be clotted for 2 hours at room temperature
  • Suitable needle gauges range from 19 – 22 for the serum based tests
  • Centrifugation should be performed at 1,500 × g for 15 or more minutes
  • Aliquots are frozen (<= -20ºC) before shipping and shipped on dry ice (-78.5ºC

EDTA Whole Blood
EDTA anticoagulated whole blood is the specimen of choice for molecular genetic tests.

Please follow the listed suggestions for collection of genetic samples.

  • Blood should be drawn directly into anticoagulant if possible
  • This must be a closed system draw to prevent contamination
  • All tubes should be inverted at least 4 times to ensure adequate mixing
  • Suitable needle gauges range from 19 – 22 to prevent cell lysis
  • A minimum of 2mL of whole blood is needed for genetic assays
  • No processing is required for this sample type
  • Ship this type of specimen at room temperature

Aliquoting Specimens
Submitting multiple aliquots (plasma or serum) for testing is an important aspect of clot, chromogenic and ELISA based tests. Aliquots of 1mL are requested for most of our assays. These should be frozen prior to shipment in a <= -20 C freezer or colder. Tubes should be placed into a rack to ensure the samples are frozen properly in the base of the tube. Freezing should occur within 1 hour of the time of draw. Please refer to the preferred number of aliquots when submitting samples.

Shipping

Shipment is a crucial aspect of clinical testing. Please follow the below instructions for easy shipments to the lab.

Local Shippers
Machaon Diagnostics contracts with Medical Couriers, Inc. (MCI). who service the entire San Francisco Bay Area and surrounding areas. MCI has a fleet of specially trained drivers that will visit your lab, clinic or office during specified times. Couriers carry dry ice, cold packs and room temperature containers for receipt of all specimen types.

Medical Couriers, Inc. can be phoned for individual pickup requests at the below number.

Medical Couriers, Inc.
(800)-652-1147

Place prepared samples and order forms in a shipping bag with Machaon and specimen type written in a clear and visible location.

Out-of-area Shippers
Please collect the following items:

  • Test Order Form
  • Packing material or newspaper
  • Styrofoam container, possibly with outer cardboard box
  • Packaging tape
  • Airbill for overnight shipments
  • ORM-A label for dry ice shipments (UN1845)
  • Dry ice (-78.5ºC) sufficient for transit time (5lb. per day)
  • Specimens in biohazard specimen transport bag

Packaging
Place the biohazard bag containing samples and the test order form into a Styrofoam container followed by dry ice. Fill remaining container space with packaging material and seal with packaging tape. Adhere a completed airbill and dry ice labels to the exterior of container in a visible location. Telephone your preferred overnight courier to request a pickup or place container in designated pickup area.

Please contact the lab with any shipping questions

Education and Publications

Podcasts

Education

Antiphospholipid Syndrome: criteria, non-criteria and triple positive testing – a video with Dr. Brad Lewis and Dr. Sciascia.

 

Platelet Functional Defects, from the clinic to genetics (a webinar given by Dr. Brad Lewis, Feb. 24, 2017)

Diagnosing Thrombotic Microangiopathies: TTP and atypical HUS: (A Grand Rounds presentation at Mattel Children’s Hospital, UCLA, to Pediatric Nephrology with Dr. Brad Lewis.)

A guide to the video content:

00:24 – Introduction (Why we should care about diagnosis of aHUS and TTP)
1:00 – What is microangiopathic hemolytic anemia (MAHA)?
1:16 – Blood smear with schistocytes
1:40 – Von Willebrand’s protein synthesis
02:09 – ADAMTS-13 and TTP pathophysiology
02:43 – How to interpret ADAMTS-13 activity testing and advantage of doing ADAMTS-13 activity testing with Machaon Dx
03:48 – Use of ADAMTS-13 testing to diagnose “Occult” TTP
04:40 – Ruling in or out aHUS with ADAMTS-13 activity testing
05:20 – Plasma exchange for aHUS patients
05:57 – The complement cascade and aHUS pathophysiology
08:04 –aHUS patients respond to eculizumab therapy
08:45 – Unlike TTP, aHUS has triggers in 70% of cases
09:26 – aHUS is a multisystem microvascular disease (aHUS-induced organs damage)
10:09 – aHUS presentation
11:41 – Can we differentiate TTP and aHUS clinically?
12:15 – 5 reasons why you should care about aHUS patients genotyping
14:17 – Advantage of doing aHUS genetic testing with Machaon Dx
14:52 – The punchline: aHUS and TTP diagnosis algorithm

Publications

Stromsness B. et al. Perceived clinical utility of ADAMTS-13 testing decreases quickly when turnaround time extends beyond two days. Int J Lab Hematol. 2015; (abstract).

Ero M. et al. Novel variant detection is essential when attempting to genetically confirm the clinical diagnosis of complement-mediated thrombotic microangiopathies (TMA). J Clin Apheresis. 2015; (abstract O-09).

Harbert J. et al. Inhibitory effects of fish oil on platelet-associated thrombin generation as measured by the calibrated automated thrombogram: an in vitro study. Int Soc Thromb Hemost 2014; (abstract 604).

Ero M. et al. Impact of telavancin on prothrombin time and activated partial thromboplastin time as determined using point-of-care coagulometers. J Thromb Thrombolysis. 2013;38(2):235-240.

Beattie DT. Et al. An in vitro investigation of the cardiovascular effects of the 5-HT4 receptor selective agonists, Velusetrag and TD-8954. J Thromb Thrombolysis. Vascular Pharmacology. 2013;58:150–156.

Ero M. et al. A pilot study on the serum pharmacokinetics of nattokinase in humans following a single oral daily dose. Alternative Therapies. 2013;19(3): 18-21.

Higgins D. et al. The inability of tegaserod to affect platelet aggregation and coronary artery tone at supratherapeutic concentrations. Archives of Pharmacology. 2012;385(1):103-9.

Ng C. et al. Oral bioavailability of nattokinase (NSK-SD). Am J Clin Pathol. 2010;134(suppl):11.

Lakshmi P. et al. Flavocoxid, an anti-inflammatory agent of botanical origin, does not affect coagulation or interact with anticoagulation therapies. Adv Ther. 2010;27(7):1-12.

Jeske WP. et al. Isolation and characterization of heparin from tuna skins. Clin Appl Thromb Hemost. 2007 Apr;12(2):137-45.

Fareed D. et al. Nitric oxide levels are upregulated in patients with malignancy-associated hypercoagulable state. Int J Lab Hematol. 2005; (abstract).

Jeske WP. et al. A survey of venous thrombosis models. Methods Mol Med. 2004;93:221-37.

Sahud et al. von Willebrand factor-cleaving protease inhibitor in a patient with human immunodeficiency syndrome-associated thrombotic thrombocytopenic purpura. Br J Haematol. 2002; 116(4):909-911.

Fenton JW. et al. Statin drugs and dietary isoprenoids downregulate protein prenylation in signal transduction and are antithrombotic and prothrombolytic agents. Biochemistry. 2002;67(1):85-91.

Ero M. et al. Comparative effects of a novel sulfated pentamannan oligosaccaride mixture (PI-88), heparin and related agents on the tissue factor-induced platelet activation and aggregation profile in whole blood. Thromb Haemost. 2001; (abstract 6260).

Ero M. et al. An antiplatelet drug, ticlopidine, inhibits heparin-induced thrombocytopenia responses as measured by platelet aggregometry and 14C serotonin release. Thromb Haemostasis. 1997; (abstract).

Clinical Trial Services

Machaon Diagnostics provides a rapid and complete solution for companies in need of clinical trial services, contract research and independent marketing claim validation. Our team of scientists has over 100 years of clinical study expertise. Machaon Diagnostics has been performing studies on pharmaceuticals, dietary supplements, functional foods and other agents since 2003. Design, subject recruitment, sample collection/storage, testing, statistical analysis, study reporting and manuscript preparation are all included in our comprehensive service. We have an extensive database of well-characterized study volunteers, allowing us to provide some IRB-approved clinical trials in as little as 1 month. Our subject database includes normal adult, elevated risk of cardiovascular disease, high blood pressure, metabolic syndrome and other populations.

Machaon Diagnostics is a California-licensed, CLIA-accredited, College of American Pathologists (CAP)-accredited clinical laboratory authorized to provide high complexity clinical laboratory services. All laboratory testing is controlled within our Quality Assurance Program and studies are offered in a Good Laboratory Practices (GLP, 21CFR Part 58)/ EN 13612 environment.

Research & Development

Machaon Diagnostics is California’s only independent specialized coagulation lab. We are a privately owned company, staffed by CA-licensed clinical laboratory scientists under the direction of a hematologist medical director.

As a clinical lab, we provide a unique testing environment for evaluating thrombotic, fibrinolytic potential. Pharmaceutical, device and biotech compounds and materials can be studied within established, validated and controlled clinical assays with verified reference ranges. Our clinical tests are further controlled within our quality assurance and proficiency testing policies and procedures. All tests can be modified or re-designed for best-fit analysis.

Machaon Diagnostics is a California-licensed, CLIA-accredited, College of American Pathologists (CAP)-accredited clinical laboratory authorized to provide high complexity clinical laboratory services. All laboratory testing is controlled within our Quality Assurance Program and studies are offered in a Good Laboratory Practices (GLP, 21CFR Part 58)/ EN 13612 environment.

The Machaon Diagnostics laboratory facility is located on a medical center campus in Oakland, California with a second lab site in New Orleans, Louisiana and is staffed with over 100 years of in-house esoteric coagulation and platelet testing experience. All lab scientists are published in and passionate about the field thrombosis and hemostasis. Please contact us if we may help with your next study.

Please contact the laboratory to inquire about this service.

Assay Development

Medical procedures, devices, novel agents and methodologies must be evaluated for their impact on coagulation and platelet systems if there is suspected bleeding or clotting potential.

Our staff has had extensive experience designing unique testing systems or applying the proper testing system to answer the client’s questions quickly and accurately.

Machaon Diagnostics is a California-licensed, CLIA-accredited, College of American Pathologists (CAP)-accredited clinical laboratory authorized to provide high complexity clinical laboratory services. All laboratory testing is controlled within our Quality Assurance Program and studies are offered in a Good Laboratory Practices (GLP, 21CFR Part 58)/ EN 13612 environment.

Please contact the laboratory to inquire about this service.

Patients

What you need to know

If you are reading this page, it likely means your doctor has ordered a bleeding or clotting test for you and would like you to get this test run at Machaon Diagnostics. Machaon Diagnostics is a clinical reference lab specializing in bleeding and clotting testing, one of the few independent coagulation labs in the country. We run very specific, unique blood tests which are often critical in helping doctors determine the correct course of treatment.

Machaon Diagnostics provides specialized lab testing to hospitals and doctors all over the country and is recognized for the speed and quality of our testing.

It is important to know that your insurance may or may not cover your testing. We have a long track record of working with patients to ensure they get the testing they need and we will work with you to help find a solution should your insurance not cover the testing we would provide.

If you are coming in to Machaon for a test, here are some things you will need to have with you:

  • Your doctors lab order
  • Your insurance information
  • Your identification
  • A list of your current medications
  • If you are coming in for a Platelet Aggregation, please remember you must fast before this test.

Machaon Diagnostics was founded in 2003 and is a California-licensed, CLIA-accredited, College of American Pathologists (CAP)-accredited clinical laboratory authorized to provide high complexity clinical laboratory services. All laboratory testing is controlled within our Quality Assurance Program and studies are offered in a Good Laboratory Practices (GLP, 21CFR Part 58)/ EN 13612 environment.

Please contact the laboratory if you have questions.